Alamri Turki, Anwer Fahad, Butt Nadeem S, Alganmi Ahmed H, Alotaibi Sultan A, Alzibali Khalid F, Hawsawi Hassan A, Bakarman Marwan, Malik Ahmad Azam
Department of Family and Community Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Department of Medicine, Faculty of Medicine in Rabigh, King Abdulaziz University, Jeddah, SAU.
Cureus. 2023 Oct 16;15(10):e47136. doi: 10.7759/cureus.47136. eCollection 2023 Oct.
The COVID-19 pandemic has brought vaccination to the forefront of global attention. The Pfizer-BioNTech vaccine, an mRNA vaccine that encodes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) glycoprotein spike, has emerged as a significant player in global vaccination efforts. It is generated from lipid nanoparticles and has been subject to various regulatory approvals and authorizations. The United Kingdom became the first country to approve the Pfizer vaccine on December 2, 2020. The World Health Organization (WHO) authorized the emergency use of the Pfizer vaccine on December 31, 2020, facilitating its production and distribution worldwide. In Saudi Arabia, as well as globally, concerns about the safety and effectiveness of vaccines have been raised. Several studies have reported side effects of the Pfizer vaccine, including rare conditions such as myocarditis. In our study, we aimed to systematically investigate the symptoms experienced after vaccination, considering the administration of three doses. We also explored the duration of these symptoms and whether they necessitated hospital visits, primary healthcare interventions, or resolved on their own. Our study employed an online cross-sectional design conducted in Jeddah, Saudi Arabia, utilizing an online self-reported survey. A total of 332 participants who met the predefined criteria were recruited for the study. The rate of COVID-19 infection after 1st and 2nd doses of Pfizer and AstraZeneca vaccines was significantly lower in middle-age subgroups (31-45 years), in comparison to young (18-30 years) and upper middle-age subgroups (46-60 years). For the AstraZeneca vaccine, the infection rate in the middle-aged group was higher after 2nd dose as compared to its 1st dose. Overall, greater infection rates were observed in upper-middle-aged subgroups with all doses of Pfizer and AstraZeneca vaccines. Fatigue and fever were the most common generalized side effects while redness/swelling/pain at the injection site, muscle pain, and joint pain were the most important local side-effects. Fatigue, fever, muscle pain, and joint pain were significantly common after 1st dose of Pfizer and fever was a significant side effect after 2nd dose of Pfizer in comparison to AstraZeneca doses. Understanding the spectrum of side effects associated with the vaccine is crucial for healthcare professionals and individuals receiving the vaccine, as it enables informed decision-making and appropriate management of potential adverse reactions.
新冠疫情使疫苗接种成为全球关注的焦点。辉瑞 - 生物科技疫苗是一种信使核糖核酸(mRNA)疫苗,编码严重急性呼吸综合征冠状病毒2(SARS-CoV-2)糖蛋白刺突,已成为全球疫苗接种工作中的重要角色。它由脂质纳米颗粒制成,并已获得各种监管批准和授权。英国于2020年12月2日成为首个批准辉瑞疫苗的国家。世界卫生组织(WHO)于2020年12月31日授权紧急使用辉瑞疫苗,促进了其在全球的生产和分发。在沙特阿拉伯以及全球范围内,人们对疫苗的安全性和有效性都提出了担忧。多项研究报告了辉瑞疫苗的副作用,包括心肌炎等罕见情况。在我们的研究中,我们旨在系统地调查接种疫苗后出现的症状,考虑接种三剂的情况。我们还探讨了这些症状的持续时间,以及它们是否需要就医、接受初级医疗干预或自行缓解。我们的研究采用了在沙特阿拉伯吉达进行的在线横断面设计,利用在线自我报告调查。共有332名符合预定标准的参与者被招募到该研究中。与年轻(18 - 30岁)和上中年亚组(46 - 60岁)相比,第一剂和第二剂辉瑞疫苗及阿斯利康疫苗接种后,中年亚组(31 - 45岁)的新冠感染率显著更低。对于阿斯利康疫苗,中年组第二剂接种后的感染率高于第一剂。总体而言,所有剂量的辉瑞和阿斯利康疫苗在上中年亚组中的感染率更高。疲劳和发热是最常见的全身性副作用,而注射部位的红肿/肿胀/疼痛、肌肉疼痛和关节疼痛是最重要的局部副作用。与阿斯利康疫苗各剂次相比,第一剂辉瑞疫苗接种后疲劳、发热、肌肉疼痛和关节疼痛显著常见,第二剂辉瑞疫苗接种后发热是显著副作用。了解与疫苗相关的副作用范围对于医护人员和接种疫苗的个人至关重要,因为这有助于做出明智的决策并对潜在不良反应进行适当管理。